five

Available datapackage for study 'A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy'

收藏
DataCite Commons2026-04-27 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/dataPackages/PR00009948.0
下载链接
链接失效反馈
官方服务:
资源简介:
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
提供机构:
Vivli
创建时间:
2026-04-27
二维码
社区交流群
二维码
科研交流群
商业服务